Soliton — Investor Presentation (September 2019)
36 slides from Soliton's investor presentation, Sep 19, 2019
Slide 1: Rapid Acoustic Pulse Technology
soliton Rapid Acoustic Pulse Technology (Nasdaq: SOLY)
Slide 2: Legal Disclaimer
Legal Disclaimer Al statements contained herein other then staternents of historical fact. including statements regarding ou future results of operations and {rancial postion, our business strategy and plans, and cur objectives fr future operations, are forward-looking statements. The words "believe
Slide 3: Overview Summary
Overview Summary Breakthrough acoustic shockwave device using novel and proprietary Rapid Acoustic Pulse (RAP) technology Induces mechanical éerupton to targeted cellar lvl structures and vacuoles No cavitation het or cotateraltesue damage or pain Platform technology Tattoo removal nas ite es 1/8 th
Slide 4: Brief History
Brief History Started 2012 with technology from MD Anderson MDAnderson Cancer Center ‘Ganeer Center Founding inventor, from MIT, originated technology Nir that became Dexcom ($11 billion valuation as of 12/31/18) Techno $32 million investment by single Venture Capital Fund pexconr (also participated
Slide 5: Management and Directors
Management and Directors All life science veterans Multiple device clearances Multiple national and international aesthetic device launches
Slide 6: Science Advisory Board
Science Advisory Board High profile Key Opinion Leaders Strong podium presence Respected, published searchers Also members of Allergan's CoolSculpting Medical Advisory Board
Slide 7: RAP Device
RAP Device
Slide 8: Electrode Cartridge
Electrode Cartridge Electro-hydraulics (arc plasma in saline) utlizes 3000 volts at 3000 amps; creates shockwaves from 2 to 6 MPa @ 100 Hz Electronic wave shaping enables very high repetition rate; reduces unwanted frequencies that cause heat and pain Custom designed reflector eliminates cavitation,
Slide 9: Soliton's Rapid Acoustic Pulse
Slide 10: RAP Therapeutic Effect
RAP Therapeutic Effect Physical Effects ECM/Fibrous Septa disruption (Acoustic subcision) Non-cavitation/non-thermal physical effects + Biological Effects (from Mechanotransduction) * Collagenesis ‘Angiogenesis | Lymphangiogenesis + Inflammation inhibition
Slide 11: Acoustic ECM Disruption-- Breakthrough
Acoustic ECM Disruption-- Breakthrough Septa Disruption Time Dose Response Kaye conmel— ee Ona TS, Sey Pits foams Ue nTONO ENE Bio Head: Omega set at higher power 2800y, 100H2, 70ms) ‘Control- 20x 1min-20x 2 min-20x 3 min-20x
Slide 12: Platform Technology
Platform Technology
Slide 13: Targeted Indications Pathway
Targeted Indications Pathway
Slide 14: Tattoo Removal: First Indication
Tattoo Removal: First Indication
Slide 15: Million Americans want some form of tattoo removal
44 million Americans want some form of tattoo removal 6356" are ‘considering Total US _ ‘Aout Popuiation removal; 28% are *regretters™ Us prospects So, why isn’t this already a billion dollar business? soliton
Slide 16: A complete removal for this patient could mean repeating this visit
A complete removal for this patient could mean repeating this visit 10 or ~ more times over the next 1 to 2 years (December 2012 Archives of Dermatology) Reducing this timeline will truly change the industry approach soliton
Slide 17: RAP Device Enables Multiple Laser Treatments In One Visit
RAP Device Enables Multiple Laser Treatments In One Visit more office FDA clearance clinical trials: i a trial par Demonstrated that Soliton’s RAP device erisoed iMate enables multiple laser passes in a single isk of scarring or ghosting Office visit Overall better outcome Achieved tattoo fading res
Slide 18: Statistically Significant Clinical Results
Statistically Significant Clinical Results Fading After 3 Treatments oy After approximately 3 office * visits, the Soliton RAP in s03% delivered 75% or greater i ea fading in 100% of patients* i ~ Soliton outperformed “laser- i = = 187% only” 100%” of the time ~ Softon « . F LaserOnly “Pes presrtd t
Slide 19: Complete removal of treated ink after treatments
Complete removal of treated ink after 3 treatments After 8 Treatments
Slide 20: Complete removal of treated ink after treatments
Complete removal of treated ink after 3 treatments Before After 3 Treatments
Slide 21: Compared with historical controls, Soliton RAP changes the removal timeline
Compared with historical controls, Soliton RAP changes the removal timeline 8 & — Soiton fang 280%) — Sotton (facing 275%) — Arch Derm Study, Laser-Only 8 Cumulative Success Rate, % 8 a % No. of Treatment Sessions
Slide 22: Cellulite Treatment: Second Indication
Cellulite Treatment: Second Indication
Slide 23: Cellulite
Cellulite Cellulite is formed in the subdermal fat layer In this region, fat cells are arranged in chambers ‘surrounded by bands of fiorous septa In certain types of cellulite, the septa can contract and become sclerotic holding portions of the skin with a non-fiexible length of septa This results i
Slide 24: Acoustic subcision device: mechanism of action
Acoustic subcision device: mechanism of action (ur device emits rapid acoustic shock wave pulses that are transmitted through the skn to breakthe = fibrotic septa = Defects or depressions are lifted by the releasing action of the procedure Direct mechanism is shearing and tearing induced by shock wa
Slide 25: Acoustic subcision device: Procedure
Acoustic subcision device: Procedure * 20-30 minute procedure can treat much of aleg/buttock area + Non-invasive: Real “incision-less” procedure Skin never punctured + No anesthetic required + Physician oversight of delivery; delegable * No recovery time soliton
Slide 26: Results: Efficacy
Results: Efficacy Efficacy + 100% correct selection of the before and 12-week post-treatment photos by 49 all binded reviewers + At26 weeks, average reduction of the Cellulite Severity Soale (CSS) to 2.93 a" from 4.27 (p<0.001) Participant Perception of Improvement and = Eatin + 40f5 self reported i
Slide 27: Clinically significant cellulite reduction with RAP
Clinically significant cellulite reduction with RAP Before 26 Weeks After Single Treatment Before and 26-weeks after a single 20-minute RAP treatment
Slide 28: Subject impression of esthetic improvement
Subject impression of esthetic improvement ‘Subject Esthetic improvement (week 26) : ce Se : Times 3 F NO CHANGE 2 a os i Pt001 Pt002 PrOO3 PLOO4 PY00S Aye (n=5)
Slide 29: Keloid and Hypertrophic Scar Treatment: Third Indication
Keloid and Hypertrophic Scar Treatment: Third Indication and Support for Other Fibrotic Disease Targets soliton
Slide 30: RAP Treatment of Fibrosis: Theory
RAP. Tidatnent of Fibrosis: Theory RAP Treatment for Fibrosis
Slide 31: Our Pipeline in Fibrosis
Our Pyle in Fibrosis
Slide 32: Revenue Potential
Revenue Potential Tattoo opportunity: Global market projected to be over S4B by 2023* & e Cellulite opportunity: me |! Global market projected to be | over $1.4B by 2026"* Keloid/Hypertrophic Scar opportunity: Global market projected to be $10B by 2025"
Slide 33: Device and revenue strategy
Device and revenue strategy | “razor and blade” recurring revenue mode! Replaceable consumable cartridge good for one patient visit Sell or lease Hand piece contains consoles replaceable cartridge
Slide 34: Key Milestones
Key Milestones Milestone Anticipated Timing FDA Approval for Tattoo Indication A Completed May 2019 Coalluite POC study- 26-week time point | A completed May 2019 Calluite POC 26-week data release in Las Vegas Aesthetics Show A Completed Juy 2019 Pivotal trial for Calle to be inated A. Completed Mid
Slide 35: Capitalization Table
Capitalization Table {as of August 31, 2019) ‘Common Stock 16,268,545 | Warrants 888,333) $9.53 Options 2,843,550) $2.59 Convertible Debt 136,517) $0.175) TOTAL FDSO 20,136,945|
Slide 36: Thank you
soliton Rapid Acoustic Pulse Technology (Nasdaq: SOLY) Thank you